Abstract: A computer system receives a definition of a group that includes an indication of a hierarchal rank of group members, a plurality of content items that correspond to the group, and identifying information indicating at least one group member that corresponds to a content item. A search input by a first user is detected and an indication of a hierarchal rank for the first user is stored. Determining a weight to assign to a search result includes comparing a hierarchal rank of at least one group member that corresponds to the first content item with the hierarchal rank of the first user.

Abstract: In some embodiments, the present disclosure describes a method that includes at least: receiving, by a processor, audience data identifying candidate audience for a website content; generating a plurality of audience groups based on the audience data; receiving user identifying data of a user; generating personalized online content for the user; tagging the personalized online content with a plurality of dynamic tokens to form trackable personalized online content; transmitting instructions to display the trackable personalized online content on a screen of a computing device; receiving user activity tracking data; training a machine learning algorithm, based on the user activity tracking data, to obtain a trained machine learning content recommendation engine; and utilizing the trained machine learning content recommendation engine to identify updated trackable personalized online content based on a plurality of markups to the trackable personalized online content.

Abstract: The present disclosure provides methods and compositions that include a polynucleotide that includes nucleic acids that encode an anti-idiotype polypeptide, as well as polypeptides that are encoded by the same, and cells that include and express the polypeptide. Disclosed methods include methods that utilize the anti-idiotype polypeptides as safety switches when they are used in combination with antibodies, include approved biologic antibodies, that include the recognized idiotype. Certain embodiments include anti-idiotype polypeptides and nucleotides encoding the same, that include an internal domain. This internal domain in some embodiments has functional domains that can induce proliferation or cell death upon binding of the anti-idiotype polypeptide by its target antibody.

Abstract: A method includes receiving signaling indicative of performance of a reset operation involving a first physical function associated with a controller of a memory device and initiating a first timer that corresponds to an amount of time available for the first physical function associated with the controller of the memory device to complete execution of pending commands. The method further includes initiating a second timer that corresponds to an amount of time available for a second physical function associated with the controller of the memory device to complete execution of pending commands and initiating a third timer that corresponds to an amount of time available for the second physical function associated with the controller of the memory device to join a recovery operation that is instigated as a result of performance of the reset operation.

Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

Abstract: A method includes receiving signaling indicative of performance of a reset operation involving a first physical function associated with a controller of a memory device and initiating a first timer that corresponds to an amount of time available for the first physical function associated with the controller of the memory device to complete execution of pending commands. The method further includes initiating a second timer that corresponds to an amount of time available for a second physical function associated with the controller of the memory device to complete execution of pending commands and initiating a third timer that corresponds to an amount of time available for the second physical function associated with the controller of the memory device to join a recovery operation that is instigated as a result of performance of the reset operation.

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration for in vitro fertilization, as well as administration of molecules, or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration for in vitro fertilization, as well as administration of molecules, or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells. In some embodiments, the methods include reaction mixtures, and resulting cell formulations, that are created using whole blood, or a component thereof that is not a PBMC, and additionally comprise T cells and recombinant retroviral particles having polynucleotides that encode a CAR. In some embodiments, modified lymphocytes are reintroduced into a subject subcutaneously. In some embodiments, polynucleotides that provide T cells the ability to regulate cell survival and proliferation in response to binding to a CAR, are provided.

Abstract: The present disclosure provides chimeric antigen receptors (CARs), and nucleic acids comprising nucleotide sequences encoding the CARs, that bind to HER2, and conditionally active biologic (CAB) CARs that bind to HER2. The present disclosure provides cells genetically modified to produce the CARs, delivery suspensions comprising these genetically modified cells, and methods for making such cells. The CARs of the present disclosure can be used in various methods, which are also provided, including methods for activating immune cells under certain conditions, and methods for performing adoptive cell therapy such as CAR therapy, for example CAR therapy against cancer.

Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells. In some embodiments, the methods include reaction mixtures, and resulting cell formulations, that are created using whole blood, or a component thereof that is not a PBMC, and additionally comprise T cells and recombinant retroviral particles having polynucleotides that encode a CAR. In some embodiments, modified lymphocytes are reintroduced into a subject subcutaneously. In some embodiments, polynucleotides that provide T cells the ability to regulate cell survival and proliferation in response to binding to a CAR, are provided.

Abstract: A computer system receives a definition of a group that includes an indication of a hierarchal rank of group members, a plurality of content items that correspond to the group, and identifying information indicating at least one group member that corresponds to a content item. A search input by a first user is detected and an indication of a hierarchal rank for the first user is stored. Determining a weight to assign to a search result includes comparing a hierarchal rank of at least one group member that corresponds to the first content item with the hierarchal rank of the first user.

Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells. In some embodiments, the methods include reaction mixtures, and resulting cell formulations, that are created using whole blood, or a component thereof that is not a PBMC, and additionally comprise T cells and recombinant retroviral particles having polynucleotides that encode a CAR. In some embodiments, modified lymphocytes are reintroduced into a subject subcutaneously. In some embodiments, polynucleotides that provide T cells the ability to regulate cell survival and proliferation in response to binding to a CAR, are provided.

Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

Abstract: A computer system receives data that includes indications of a plurality of agenda items that correspond to the group event. During the group event, the system captures, by a media recording device, media data, converts the captured media data to a searchable version of the media data and searches the searchable version of the media data to determine a first time frame of the media data that corresponds to a first agenda item of the plurality of agenda items. The system displays, in a user interface that is accessible to at least one user associated with the group event, the representation of the media data. A first portion of the representation of the media data that corresponds to the first time frame is visually distinguished from at least a portion of the representation of the media data that does not correspond to the first time frame.

Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

Abstract: A computer system receives data that includes indications of a plurality of agenda items that correspond to the group event. During the group event, the system captures, by a media recording device, media data, converts the captured media data to a searchable version of the media data and searches the searchable version of the media data to determine a first time frame of the media data that corresponds to a first agenda item of the plurality of agenda items. The system displays, in a user interface that is accessible to at least one user associated with the group event, the representation of the media data. A first portion of the representation of the media data that corresponds to the first time frame is visually distinguished from at least a portion of the representation of the media data that does not correspond to the first time frame.

Abstract: An apparatus to facilitate memory flushing is disclosed. The apparatus comprises a cache memory, one or more processing resources, tracker hardware to dispatch workloads for execution at the processing resources and to monitor the workloads to track completion of the execution, range based flush (RBF) hardware to process RBF commands and generate a flush indication to flush data from the cache memory and a flush controller to receive the flush indication and perform a flush operation to discard data from the cache memory at an address range provided in the flush indication.

Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.